PR1001 : Prostate cancer tissue array, including WHO pathology grade and gleason grade, 25 cases/100 cores
|
Microarray Panel | Prostate carcinoma tissue microarray, containing 25 cases of adenocarcinoma, quadruple cores per case | |
Cores | 100 | |
Cases | 25 | |
Row number | 10 | |
Column number | 10 | |
Core Diameter (mm) | 1 | |
Thickness (µm) | 5 | |
Tissue Array Type | FFPE | |
Species | Human | |
Applications | Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page. | |
Notes | 1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning.
2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet,“*” means invalid core; “-” means no applicable or negative in IHC markers. |
Mouseover and click individual cores to view high resolution images.
Legend: | Pro - Prostate - Malignant tumor, - Malignant tumor (stage II), - Malignant tumor (stage III), - Malignant tumor (stage IV) |
Specification Sheet (Sortable), tissue IDs are available in exported Excel files.
Pos. | No. | Age | Sex | Organ/Anatomic Site | Pathology diagnosis | TNM | Grade | Stage | Type | Gleason Score | Gleason Grade | Image |
---|
A1 | 1 | 70 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | malignant | 3+4 | 2 | |
A2 | 2 | 64 | M | Prostate | Adenocarcinoma | T2aN0M0 | 1 | II | malignant | 2+4 | 1 | |
A3 | 3 | 78 | M | Prostate | Adenocarcinoma | T4N1M1b | 2 | IV | malignant | 3+4 | 2 | |
A4 | 4 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 4+4 | 4 | |
A5 | 5 | 75 | M | Prostate | Adenocarcinoma | T4N1M1 | 1 | IV | malignant | 2+3 | 1 | |
A6 | 6 | 70 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | malignant | 3+4 | 2 | |
A7 | 7 | 64 | M | Prostate | Adenocarcinoma | T2aN0M0 | 1 | II | malignant | 2+4 | 1 | |
A8 | 8 | 78 | M | Prostate | Adenocarcinoma | T4N1M1b | 2 | IV | malignant | 3+4 | 2 | |
A9 | 9 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 4+4 | 4 | |
A10 | 10 | 75 | M | Prostate | Adenocarcinoma | T4N1M1 | 1 | IV | malignant | 2+3 | 1 | |
B1 | 11 | 70 | M | Prostate | Adenocarcinoma | T2N1M1c | 2 | IV | malignant | 3+4 | 2 | |
B2 | 12 | 62 | M | Prostate | Adenocarcinoma | T3N1M1h | 2 | IV | malignant | 3+4 | 2 | |
B3 | 13 | 76 | M | Prostate | Adenocarcinoma | T2aN0M0 | 2 | II | malignant | 3+4 | 2 | |
B4 | 14 | 62 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
B5 | 15 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 4+5 | 5 | |
B6 | 16 | 70 | M | Prostate | Adenocarcinoma | T2N1M1c | 2 | IV | malignant | 3+4 | 2 | |
B7 | 17 | 62 | M | Prostate | Adenocarcinoma | T3N1M1h | 2 | IV | malignant | 3+4 | 2 | |
B8 | 18 | 76 | M | Prostate | Adenocarcinoma | T2aN0M0 | 1 | II | malignant | 2+2 | 1 | |
B9 | 19 | 62 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
B10 | 20 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 4+5 | 5 | |
C1 | 21 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | II | malignant | 3+4 | 2 | |
C2 | 22 | 82 | M | Prostate | Adenocarcinoma | T3N2M1 | 2 | IV | malignant | 5+5 | 5 | |
C3 | 23 | 66 | M | Prostate | Adenocarcinoma | T3aN0M0 | 2 | III | malignant | 3+4 | 2 | |
C4 | 24 | 76 | M | Prostate | Adenocarcinoma | T3N1M1b | 3 | IV | malignant | 5+5 | 5 | |
C5 | 25 | 76 | M | Prostate | Adenocarcinoma (sparse) | T2aN0M0 | - | II | malignant | 2+5 | 3 | |
C6 | 26 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | II | malignant | 3+4 | 2 | |
C7 | 27 | 82 | M | Prostate | Adenocarcinoma | T3N2M1 | 2 | IV | malignant | 3+5 | 4 | |
C8 | 28 | 66 | M | Prostate | Adenocarcinoma | T3aN0M0 | 3 | III | malignant | 3+4 | 2 | |
C9 | 29 | 76 | M | Prostate | Adenocarcinoma | T3N1M1b | 3 | IV | malignant | 5+5 | 5 | |
C10 | 30 | 76 | M | Prostate | Adenocarcinoma (sparse) | T2aN0M0 | - | II | malignant | 2+5 | 3 | |
D1 | 31 | 73 | M | Prostate | Adenocarcinoma | T3N1M1 | 3 | IV | malignant | 5+5 | 5 | |
D2 | 32 | 60 | M | Prostate | Adenocarcinoma | T3N1M0 | 2 | IV | malignant | 2+5 | 3 | |
D3 | 33 | 73 | M | Prostate | Adenocarcinoma | T4N1M1c | 2 | IV | malignant | 5+5 | 5 | |
D4 | 34 | 77 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | II | malignant | 2+5 | 3 | |
D5 | 35 | 55 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
D6 | 36 | 73 | M | Prostate | Adenocarcinoma | T3N1M1 | 3 | IV | malignant | - | - | |
D7 | 37 | 60 | M | Prostate | Adenocarcinoma | T3N1M0 | 2 | IV | malignant | 2+5 | 3 | |
D8 | 38 | 73 | M | Prostate | Adenocarcinoma | T4N1M1c | 2 | IV | malignant | 5+5 | 5 | |
D9 | 39 | 77 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
D10 | 40 | 55 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
E1 | 41 | 60 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
E2 | 42 | 87 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
E3 | 43 | 81 | M | Prostate | Adenocarcinoma | T2aN0M0 | 3 | III | malignant | 4+5 | 5 | |
E4 | 44 | 75 | M | Prostate | Adenocarcinoma | T2N1M1c | 3 | IV | malignant | 5+5 | 5 | |
E5 | 45 | 80 | M | Prostate | Adenocarcinoma | T4N1M1c | 1 | IV | malignant | 2+3 | 1 | |
E6 | 46 | 60 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
E7 | 47 | 87 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
E8 | 48 | 81 | M | Prostate | Adenocarcinoma | T2aN0M0 | 3 | III | malignant | 4+5 | 5 | |
E9 | 49 | 75 | M | Prostate | Adenocarcinoma | T2N1M1c | 3 | IV | malignant | 5+5 | 5 | |
E10 | 50 | 80 | M | Prostate | Adenocarcinoma | T4N1M1c | 3 | IV | malignant | 3+5 | 4 | |
F1 | 51 | 70 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | malignant | 3+4 | 2 | |
F2 | 52 | 64 | M | Prostate | Adenocarcinoma | T2aN0M0 | 1 | II | malignant | 2+4 | 1 | |
F3 | 53 | 78 | M | Prostate | Adenocarcinoma | T4N1M1b | 2 | IV | malignant | 3+5 | 4 | |
F4 | 54 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | II | malignant | 4+4 | 4 | |
F5 | 55 | 75 | M | Prostate | Adenocarcinoma | T4N1M1 | 1 | IV | malignant | 2+3 | 1 | |
F6 | 56 | 70 | M | Prostate | Adenocarcinoma (prostate tissue) | T3N0M0 | - | III | malignant | - | - | |
F7 | 57 | 64 | M | Prostate | Adenocarcinoma | T2aN0M0 | 1 | II | malignant | 2+4 | 1 | |
F8 | 58 | 78 | M | Prostate | Adenocarcinoma | T4N1M1b | 2 | IV | malignant | 3+4 | 2 | |
F9 | 59 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | II | malignant | 4+4 | 4 | |
F10 | 60 | 75 | M | Prostate | Adenocarcinoma | T4N1M1 | 2 | IV | malignant | 2+3 | 1 | |
G1 | 61 | 70 | M | Prostate | Adenocarcinoma | T2N1M1c | 2 | IV | malignant | 3+4 | 2 | |
G2 | 62 | 62 | M | Prostate | Adenocarcinoma | T3N1M1h | 2 | IV | malignant | 3+4 | 2 | |
G3 | 63 | 76 | M | Prostate | Adenocarcinoma | T2aN0M0 | 2 | II | malignant | 3+4 | 2 | |
G4 | 64 | 62 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
G5 | 65 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 4+5 | 5 | |
G6 | 66 | 70 | M | Prostate | Adenocarcinoma | T2N1M1c | 2 | IV | malignant | 4+3 | 3 | |
G7 | 67 | 62 | M | Prostate | Adenocarcinoma | T3N1M1h | 2 | IV | malignant | 4+3 | 3 | |
G8 | 68 | 76 | M | Prostate | Adenocarcinoma | T2aN0M0 | 2 | II | malignant | 4+3 | 3 | |
G9 | 69 | 62 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
G10 | 70 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 4+5 | 5 | |
H1 | 71 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | II | malignant | 3+4 | 2 | |
H2 | 72 | 82 | M | Prostate | Adenocarcinoma | T3N2M1 | 1 | IV | malignant | 2+2 | 1 | |
H3 | 73 | 66 | M | Prostate | Adenocarcinoma | T3aN0M0 | 2 | III | malignant | 3+4 | 2 | |
H4 | 74 | 76 | M | Prostate | Adenocarcinoma | T3N1M1b | 3 | IV | malignant | 4+5 | 5 | |
H5 | 75 | 76 | M | Prostate | Adenocarcinoma (prostate tissue) | T2aN0M0 | - | II | malignant | - | - | |
H6 | 76 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | II | malignant | 2+1 | 1 | |
H7 | 77 | 82 | M | Prostate | Adenocarcinoma | T3N2M1 | 2 | IV | malignant | 2+5 | 3 | |
H8 | 78 | 66 | M | Prostate | Adenocarcinoma | T3aN0M0 | 2 | III | malignant | 3+4 | 2 | |
H9 | 79 | 76 | M | Prostate | Adenocarcinoma | T3N1M1b | 3 | IV | malignant | 5+5 | 5 | |
H10 | 80 | 76 | M | Prostate | Adenocarcinoma | T2aN0M0 | 2 | II | malignant | 2+5 | 3 | |
I1 | 81 | 73 | M | Prostate | Adenocarcinoma | T3N1M1 | - | IV | malignant | - | - | |
I2 | 82 | 60 | M | Prostate | Adenocarcinoma | T3N1M0 | 2 | IV | malignant | 2+5 | 3 | |
I3 | 83 | 73 | M | Prostate | Adenocarcinoma | T4N1M1c | 3 | IV | malignant | 5+5 | 5 | |
I4 | 84 | 77 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | II | malignant | 2+5 | 3 | |
I5 | 85 | 55 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 3+5 | 4 | |
I6 | 86 | 73 | M | Prostate | Adenocarcinoma | T3N1M1 | 3 | IV | malignant | 5+5 | 5 | |
I7 | 87 | 60 | M | Prostate | Adenocarcinoma | T3N1M0 | 2 | IV | malignant | 2+5 | 3 | |
I8 | 88 | 73 | M | Prostate | Adenocarcinoma | T4N1M1c | 3 | IV | malignant | 5+5 | 5 | |
I9 | 89 | 77 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | II | malignant | 2+5 | 3 | |
I10 | 90 | 55 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
J1 | 91 | 60 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
J2 | 92 | 87 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
J3 | 93 | 81 | M | Prostate | Adenocarcinoma | T2aN0M0 | 3 | III | malignant | 4+5 | 5 | |
J4 | 94 | 75 | M | Prostate | Adenocarcinoma (fibrovascular) | T2N1M1c | - | IV | malignant | - | - | |
J5 | 95 | 80 | M | Prostate | Adenocarcinoma | T4N1M1c | 1 | IV | malignant | 2+4 | 1 | |
J6 | 96 | 60 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
J7 | 97 | 87 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | II | malignant | 5+5 | 5 | |
J8 | 98 | 81 | M | Prostate | Adenocarcinoma | T2aN0M0 | 3 | III | malignant | 4+5 | 5 | |
J9 | 99 | 75 | M | Prostate | Adenocarcinoma | T2N1M1c | 3 | IV | malignant | 5+5 | 5 | |
J10 | 100 | 80 | M | Prostate | Adenocarcinoma | T4N1M1c | 1 | IV | malignant | 2+4 | 1 | |
- | 0 | 55 | F | liver | Hepatocellular liver cancer (tissue marker) | T3N0M0 | 3 | Malignant |
Find overlapping cases with this tissue array:
- Product Code: PR1001
- Availability: In Stock